mycophenolate sodium + cyclosporine

Mycophenolate sodium + cyclosporine is a combination immunosuppressive therapy used primarily in transplant medicine. This combination leverages the synergistic effects of both drugs to prevent organ rejection while managing side effects. ## Mechanism of Action Mycophenolate sodium is an enteric-coated formulation that delivers mycophenolic acid (MPA), the active metabolite. MPA works by inhibiting inosine monophosphate dehydrogenase (IMPDH), an enzyme crucial for de novo purine synthesis[8]. This inhibition particularly affects T and B lymphocytes, which rely heavily on this pathway for proliferation, resulting in potent immunosuppressive effects[8]. Cyclosporine functions by inhibiting calcineurin, thereby preventing T-cell activation and cytokine production. When combined with mycophenolate, there's a significant pharmacokinetic interaction: cyclosporine decreases MPA plasma concentrations by inhibiting the biliary excretion of MPA-glucuronide (MPAG) through the multidrug resistance-associated protein 2 (Mrp2) transporter[6]. ## Clinical Applications This combination is primarily used in: - Solid organ transplantation (kidney, liver, heart) to prevent graft rejection - Treatment of certain autoimmune conditions, though with limited efficacy in some cases like steroid-resistant focal segmental glomerulosclerosis (FSGS)[5] ## Pharmacokinetics When administered together, cyclosporine affects mycophenolate metabolism in several ways: - Decreases MPA exposure while increasing exposure to its metabolite MPAG[6] - Interferes with the biliary excretion of MPAG[6] - Can lead to rapid increases in MPA concentration when combined with other drugs like posaconazole[2] ## Efficacy and Safety The combination has shown significant efficacy in transplant settings: - In myeloablative sibling donor transplantation, the combination is well-tolerated[1] - Studies in dogs demonstrated synergism between the drugs, with stable graft-host tolerance in over 50% of subjects[7] Common adverse effects include: - Gastrointestinal symptoms (most frequent but generally mild)[5] - Potential for infections, particularly when combined with other immunosuppressants[4] - Hematological effects including thrombocytopenia[4] - Metabolic disturbances such as hypercholesterolemia and hyperglycemia[4] ## Dosing Considerations Due to the pharmacokinetic interactions between these drugs, careful monitoring is recommended: - MPA concentrations may not reach target levels initially but can increase significantly without dose changes[2] - Cyclosporine concentrations may increase significantly after several weeks of combined therapy, potentially requiring dose reduction[2] - Therapeutic drug monitoring is essential for optimizing therapy and minimizing toxicity[2][3] This combination represents an important therapeutic approach in transplant medicine, balancing efficacy in preventing rejection with manageable side effects through careful monitoring and dose adjustment.

Brand names

MyforticNeoralSandimmune

Other names

cyclosporine + mycophenolic acidcyclosporin + mycophenolic acid